Table 2.

Symptom response: efficacy analyzable set^a

Stratum	Pasireotide LAR n/N (%)[95% exact CI]	Octreotide LAR n/N (%)[95% exact CI]	Between treatment OR [95% CI]
Diarrhea and flushing	5/37 (13.5) [4.5–28.8]	11/39 (28.2) [15.0–44.9]	0.40 [0.12–1.29]
Predominantly diarrhea	2/2 (100) [15.8–100]	1/5 (20.0) [0.5–71.6]
Predominantly flushing	2/4 (50.0) [6.8–93.2]	0/1 (0) [0.0–97.5]
Overall	9/43 (20.9) [10.0–36.0]	12/45 (26.7) [14.6–41.9]	0.73 [0.27–1.97] P=0.53

Note:

^aThe efficacy analyzable set consisted of the subset of the full analysis set who were randomized at least 6 months before the futility data monitoring committee data cutoff.

Abbreviations: CI, confidence interval; n/N, number of responders/number of patients analyzed; octreotide LAR, octreotide long-acting repeatable; OR, odds ratio; pasireotide LAR, pasireotide long-acting release.